From AFR Street Talk
Carlyle goes all in on biotech Opthea; MST launches $80m capital raise
Carlyle Group and its life sciences arm Abingworth are doubling down on their investment in Australian biotech Opthea in an ongoing bid to get the company’s lead therapeutic candidate OPT-302 to market, Street Talk understands.
The private equity giant has signaled its intention to take up an option to invest another $80 million in the clinical stage biotech.
I do not have access to the whole article
From AFR Street TalkCarlyle goes all in on biotech Opthea; MST...
-
- There are more pages in this discussion • 59 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add OPT (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
49.5¢ |
Change
0.005(1.02%) |
Mkt cap ! $609.3M | |||
| Open | High | Low | Value | Volume |
| 48.5¢ | 50.5¢ | 46.5¢ | $690.9K | 1.420M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 1264 | 49.5¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 50.0¢ | 15502 | 2 |
View Market Depth
| Last trade - 16.10pm 19/08/2024 (20 minute delay) ? |
| OPT (ASX) Chart |